Boston Scientific has reported positive 12-month primary endpoint outcomes from the ADVANTAGE AF trial’s second phase, ...

Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month primary endpoint results from the second phase of ...

Boston Scientific is Thursday's IBD Stock Of The Day. Shares are forming a double-bottom base, while approaching an early ...

Led by Farapulse founder Steven Mickelsen, Field has developed a pulsed field ablation device to tackle the dangerous heart ...

Boston Scientific (NYSE: BSX) today announced positive 12-month study results for its Farapulse pulsed field ablation (PFA) ...

We’re thrilled to share another significant advancement in cardiac care at CHI St. Luke’s Health, right here at the . Our ...

Boston Scientific, Medtronic, Abbott and J&J unveiled new data for their PFA devices in tandem with the Heart Rhythm ...

Boston Scientific said that while tariffs pose “unfortunate” headwinds—which are poised to add about $200 million to the cost ...

"The data collected in this trial continues to support the FARAPULSE PFA System as a safe and effective therapy, now with evidence highlighting positive results for its use in treating patients ...

Boston Scientific has reported positive 12-month primary endpoint outcomes from the ADVANTAGE AF trial’s second phase, assessing the Farapulse pulsed field ablation (PFA) system and Farapoint ...